Angiotensin II upregulates acyl-CoA:Cholesterol acyltransferase-1 via the angiotensin II type 1 receptor in human monocyte-macrophages

Hypertension Research

Volumn 31, Issue 9, 2008, Pages 1801-1810

  Kanome, Tomoko ^a   Watanabe, Takuya ^a   Nishio, Kae ^a   Takahashi, Keiko ^a   Hongo, Shigeki ^a   Miyazaki, Akira ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acyl CoA:cholesterol acyltransferase 1; Angiotensin II; Angiotensin II receptors; Atherosclerosis; Macrophage

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ACETYL LOW DENSITY LIPOPROTEIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CANDESARTAN; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE 1; CHOLESTEROL ESTER; GUANINE NUCLEOTIDE BINDING PROTEIN; HORMONE RECEPTOR STIMULATING AGENT; L 162313; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; ROTTLERIN; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; FOAM CELL; HUMAN; HUMAN CELL; MACROPHAGE FUNCTION; MONOCYTE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 55449106868     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1801     Document Type: Article

References (35)

1. Pennings M, Meurs I, Ye D, et al: Regulation of cholesterol homeostasis in macrophages and consequences for atherosclerotic lesion development. FEBS Lett 2006; 580: 5588-5596.
2. Miyazaki A, Sakashita N, Lee O, et al: Expression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1568-1574.
3. Miyazaki A, Kanome T, Watanabe T: Inhibitors of acylcoenzyme A:cholesterol acyltransferase. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 463-469.
4. Daugherty A, Manning MW, Cassis LA: Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E.deficient mice. J Clin Invest 2000; 105: 1605-1612.
5. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD: Evidence that macrophages in atherosclerotic lesions contain Ang-II. Circulation 1998; 98: 800-807.
6. Ayabe N, Suganuma E, Babaev VR, et al: Angiotensin II amplifies macrophage-driven atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 2143-2148.
7. Keidar S, Heinrich R, Kaplan M, Hayek T, Aviram M: Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler Thromb Vasc Biol 2001; 21: 1464-1469.
8. Keidar S, Attias J: Angiotensin II injection into mice increases the uptake of oxidized LDL by their macrophages via a proteoglycan-mediated pathway. Biochem Biophys Res Commun 1997; 239: 63-67.
9. Kaplan M, Aviram M, Knopf C, Keidar S: Angiotensin II reduces macrophage cholesterol efflux: a role for the AT-1 receptor but not for the ABC1 transporter. Biochem Biophys Res Commun 2002; 290: 1529-1534.
10. Okamura A, Rakugi H, Ohishi M, et al: Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999; 17: 537-545.
11. Watanabe T, Pakala R, Katagiri T, Benedict CR: Serotonin potentiates angiotensin II-induced vascular smooth muscle cell proliferation. Atherosclerosis 2001; 159: 269-279.
12. 2: implications for atherosclerotic plaque rupture. J Leukoc Biol 2005; 78: 195-201.
13. Watanabe T, Suguro T, Kanome T, et al: Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 2005; 46: 738-744.
14. Watanabe T, Nishio K, Kanome T, et al: Impact of salusin-and -β on human macrophage foam cell formation and coronary atherosclerosis. Circulation 2008; 117: 638-648.
15. Suguro T, Watanabe T, Kanome T, et al: Serotonin acts as an up-regulator of acyl-coenzyme A:cholesterol acyltransferase-1 in human monocyte-macrophages. Atherosclerosis 2006; 186: 275-281.
16. Dove DE, Su YR, Zhang W, et al: ACAT1 deficiency disrupts cholesterol efflux and alters cellular morphology in macrophages. Arterioscler Thromb Vasc Biol 2005; 25: 128-134.
17. Nahmod KA, Vermeulen ME, Radien S, et al: Control of dendritic cell differentiation by angiotensin II. FASEB J 2003; 17: 491-493.
18. 1-receptor and implications for vascular disease. J Hypertens 2006; 24: S15-S21.
19. Wassmann S, Czech T, van Eickels M, Fleming I, Bohm M, Nickenig G: Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 2004; 110: 3062-3067.
20. Rueckschloss U, Quinn MT, Holtz J, Morawietz H: Dosedependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002; 22: 1845-1851.
21. Johnstone MT, Perez AS, Nasser I, et al: Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model. Circulation 2004; 110: 2060-2065.
22. Koga M, Kai H, Yasukawa H, et al: Postnatal blocking of interferon-γ function prevented atherosclerotic plaque formation in apolipoprotein E.knockout mice. Hypertens Res 2007; 30: 259-267.
23. Cianchetti S, Fiorentino AD, Colognato R, Stefano RD, Franzoni F, Pedrinelli R: Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008; 198: 22-28.
24. Yano Y, Hoshide S, Ishikawa J, et al: The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. Am J Hypertens 2007; 20: 565-572.
25. Imakiire T, Kikuchi Y, Yamada M, et al: Effects of reninangiotensin system blockade on macrophage infiltration in patients with hypertensive nephrosclerosis. Hypertens Res 2007; 30: 635-642.
26. Fazio S, Major AS, Swift LL, et al: Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest 2001; 107: 163-171.
27. Ikenoya M, Yoshinaka Y, Kobayashi H, et al: A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis 2007; 19: 290-297.
28. Nissen SE, Tuzcu EM, Brewer HB, et al: ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators: Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006; 354: 1253-1263.
29. 1 during differentiation of human monocytes into macrophages. Biochem Biophys Res Commun 2004; 320: 501-505.
30. Furukawa K, Hori M, Ouchi N, et al: Adiponectin down-regulates acyl-coenzyme A:cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 2004; 317: 831-836.
31. Watanabe T, Pakala R, Katagiri T, Benedict CR: Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation. J Hypertens 2001; 19: 1065-1073.
32. Sadoshima J, Xu Y, Slayter HS, Izumo S: Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75: 977-984.
33. Schuijt MP, van Kats JP, de Zeeuw S, et al: Cardiac interstitial fluid levels of angiotensin I and II in the pig. J Hypertens 1999; 17: 1885-1891.
34. Ohishi M, Ueda M, Rakugi H, et al: Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 1997; 15: 1295-1302.
35. Ihara M, Urata H, Kinoshita A, et al: Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999; 33: 1399-1405.